ロード中...
Comparison of malaria treatment outcome of generic and innovator’s anti-malarial drugs containing artemether–lumefantrine combination in the management of uncomplicated malaria amongst Tanzanian children
BACKGROUND: In 2006, artemether–lumefantrine (ALU), specifically Coartem(®) (Novartis Pharma AG, Basel Switzerland), was approved as the first-line drug for treatment of uncomplicated malaria in Tanzania. Due to poor availability and affordability of the innovator’s product, the government of Tanzan...
保存先:
| 出版年: | Malar J |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
BioMed Central
2019
|
| 主題: | |
| オンライン・アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6460845/ https://ncbi.nlm.nih.gov/pubmed/30975147 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12936-019-2769-z |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|